Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine

Summary

To determine if the pharmacokinetics of high doses of zidovudine (AZT) (that is, how fast AZT reaches the blood, what concentration of AZT is attained in the blood, and how long AZT remains in the blood) changes from day to day in the same patient. Also to determine whether the pharmacokinetics of AZT is changed when trimethoprim/sulfamethoxazole (SMX/TMP) is given at the same time, or whether the pharmacokinetics of SMX/TMP is altered by AZT given at the same time. AZT has been effective in treating HIV infection in some patients with AIDS, and SMX/TMP is an antibiotic combination which is useful in preventing or treating Pneumocystis carinii pneumonia (PCP). It is important to know how drugs interact in patients because addition of a second drug may change the speed at which a drug is eliminated from the body, and cause increased toxic effects or decreased therapeutic effects.

Timeline

Start

—

Primary completion

—

Completion

1990-05

Publications

• Background Canas E, Pachon J, Viciana P, Garcia-Pesquera F, Castillo JR, Jimenez-Mejias ME. Effect of trimethoprim-sulphamethoxazole on zidovudine kinetics in HIV infected patients. Program Abstr Intersci Conf Antimicrob Agents Chemother. 1994 Oct 4-7:168

Drugs

Indications